
    
      This study is a first in human, Phase 1, open label, multicenter, dose escalation study with
      expansion at the RP2D to evaluate the safety, tolerability and preliminary antileukemic
      activity of AMV564 in patients with relapsed or refractory acute myeloid leukemia (AML).

      AMV564 will be given on Days 1-14 of a 4-week cycle, or Days 1-28 of a 6-week cycle,via CIV
      or subcutaneous administration for 1 or more treatment cycles as monotherapy or in
      combination with pembrolizumab.
    
  